Somapacitan

Also known as: Sogroya, Somapacitan-beco, NNC0195-0092

A once-weekly long-acting growth hormone, FDA-approved as Sogroya for adult (2020) and pediatric (2023) GH deficiency. Prescription medication.

Last updated October 26, 2026

Mechanism of Action

Somapacitan is human growth hormone with a single amino-acid substitution to which a fatty-acid side chain is attached. The side chain binds reversibly to circulating albumin, slowing clearance and extending the half-life so one injection a week is enough. It acts at the growth hormone receptor exactly as native GH does, raising IGF-1 and producing GH's growth and metabolic effects.

Half-life: ~2-3 days
Administration Routes: Subcutaneous
Research Status: Clinical

Reported Benefits

Once-weekly replacement for adults with GH deficiency
Height velocity non-inferior to daily somatropin in children with GH deficiency (REAL4)
Label expanded in 2026 to children born SGA, with idiopathic short stature or with Noonan syndrome

Potential Side Effects

Injection-site reactions
Headache, nasopharyngitis, arthralgia
Peripheral edema
Reduced insulin sensitivity and higher blood glucose
Class GH warnings: intracranial hypertension, slipped capital femoral epiphysis, scoliosis progression

Common Dosing

Labeled dosing is once weekly by subcutaneous injection: weight-based in children (0.16 mg/kg per week for GH deficiency) and a fixed starting dose in adults (1.5 mg weekly, higher in women on oral estrogen) that is titrated to IGF-1 and tolerability. Dosing is set and supervised by the prescribing clinician.

The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.

Contraindications

Acute critical illness after surgery, trauma, or acute respiratory failure
Active malignancy
Active proliferative or severe nonproliferative diabetic retinopathy
Hypersensitivity to somapacitan

No documented stacking partners for Somapacitan yet.

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
2020
View
Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
2022
View
Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
2023
View

Yes. Sogroya was FDA-approved for adult growth hormone deficiency in August 2020 and for pediatric growth hormone deficiency in April 2023. In February 2026 the FDA added children born small for gestational age, idiopathic short stature and Noonan syndrome.

It is the same hormone modified to bind albumin, so it lasts long enough for weekly rather than daily injections. In phase 3 trials its effect on growth and IGF-1 was comparable to daily somatropin.